{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["adagrasib","TNO155"]],"indication":"KRAS G12C-mutated advanced solid tumors","name":"KRYSTAL 2","nct_id":"NCT04330664","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krystal-2-nct04330664. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Dose escalation of TNO155 to determine maximum tolerated dose of TNO155 in combination with MRTX849","label":"Phase 1 Dose Exploration","type":"EXPERIMENTAL"},{"description":"Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with TNO155 to recommend Phase 2 regimens","label":"Phase 1b Expansion","type":"EXPERIMENTAL"},{"description":"Separate cohorts of patients stratified by histological diagnosis for evaluation of clinical activity to evaluate clinical activity of MRTX849 and TNO155 in combination","label":"Phase 2","type":"EXPERIMENTAL"}],"collaborators":["Novartis"],"completion_date":{"date":"2025-02-24","type":"ACTUAL"},"conditions":["Advanced Cancer","Metastatic Cancer","Malignant Neoplastic Disease"],"enrollment":{"count":86,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"MRTX849","otherNames":["adagrasib"],"type":"DRUG"},{"name":"TNO155","otherNames":[],"type":"DRUG"}],"last_update":"2025-04-04","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2022-07-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Characterize the safety of MRTX849 and TNO155 in patients having advanced solid tumor malignancies with KRAS G12C mutation.","timeFrame":"20 months"},{"measure":"Evaluate the pharmacokinetics of MRTX849 and TNO155","timeFrame":"20 months"}],"references":[],"start_date":{"date":"2020-04-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)","url":"https://clinicaltrials.gov/study/NCT04330664"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krystal-2-nct04330664"}